腹主动脉瘤修复患者合并症指数的开发
本研究利用美国全国住院患者样本(NIS)2015年第四季度至2020年数据,为腹主动脉瘤腔内修复(EVAR)和开放手术修复(OSR)患者分别开发合并症指数。EVAR组34668例(死亡率2.19%),OSR组4792例(死亡率10.98%);两指数区分能力中等(EVAR c统计量0.641,OSR 0.600),校准良好,且区分能力显著优于Elixhauser合并症指数(DeLong P<.001)。
要点
- EVAR合并症指数c统计量0.641(95%CI 0.616-0.665),OSR为0.600(95%CI 0.563-0.630)。
- 两指数区分能力均显著优于Elixhauser合并症指数(DeLong P<.001)。
核心结论
- 为普通人群制定的Elixhauser合并症指数在腹主动脉瘤修复患者中表现欠佳,为此开发了EVAR和OSR专用合并症指数并经内部和外部验证。
- EVAR和OSR合并症指数在区分院内死亡率方面优于Elixhauser合并症指数,可用于标准化腹主动脉瘤修复临床研究的合并症测量,尤其适用于单机构数据来源等小样本研究,以促进结果复现和跨研究比较。
研究设计与样本
- 利用美国全国住院患者样本(NIS)2015年第四季度至2020年数据,识别接受EVAR或OSR的患者。
- 每组患者随机分为实验组(2/3)和验证组(1/3),通过多变量逻辑回归确定Elixhauser合并症的权重,分别为EVAR和OSR组开发单一合并症指数。
主要发现
- 共34668例接受EVAR(死亡率2.19%),4792例接受OSR(死亡率10.98%)。
- EVAR指数c统计量0.641(95%CI 0.616-0.665),Brier评分0.021;OSR指数c统计量0.600(95%CI 0.563-0.630),Brier评分0.096。
- Elixhauser合并症指数EVAR c统计量0.572(95%CI 0.546-0.597),OSR c统计量0.502(95%CI 0.472-0.533);两新指数区分能力显著优于Elixhauser合并症指数(DeLong P<.001)。
- 内部验证中,两指数与个体合并症调整表现相似(EVAR DeLong P=.650;OSR DeLong P=.431)。
- 外部验证中,两指数与各自验证组表现相当(EVAR DeLong P=.891;OSR DeLong P=.757)。
临床怎么用
- 作者认为,EVAR和OSR合并症指数可用于标准化腹主动脉瘤修复临床研究的合并症测量,尤其适用于单机构数据来源等小样本研究,以促进结果复现和跨研究比较。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular aneurysm repair (EVAR) and open surgical repair (OSR) are two modalities to treat patients with abdominal aortic aneurysm (AAA). Alternative to individual comorbidity adjustment, a summary comorbidity index is a weighted composite score of all comorbidities that can be used as standard metric to control for comorbidity burden in clinical studies. This study aimed to develop summary comorbidity indices for patients who underwent AAA repair. METHODS: Patients who went under EVAR or OSR were identified in National Inpatient Sample (NIS) between the last quarter of 2015 to 2020. In each group, patients were randomly sampled into experimental (2/3) and validation (1/3) groups. The weights of Elixhauser comorbidities were determined from a multivariable logistic regression and single comorbidity indices were developed for EVAR and OAR groups, respectively. RESULTS: There were 34,668 patients underwent EVAR (2.19% mortality) and 4792 underwent OSR (10.98% mortality). Both comorbidity indices had moderate discriminative power (EVAR c-statistic, 0.641; 95% confidence interval [CI], 0.616-0.665; OSR c-statistic, 0.600; 95% CI, 0.563-0.630) and good calibration (EVAR Brier score, 0.021; OSR Brier score, 0.096). The indices had significantly better discriminative power (DeLong P <.001) than the Elixhauser Comorbidity Index (ECI) (EVAR c-statistic, 0.572; 95% CI, 0.546-0.597; OSR c-statistic, 0.502; 95% CI, 0.472-0.533). For internal validation, both indices had similar performance compared with individual comorbidity adjustment (EVAR DeLong P = .650; OSR DeLong P = .431). These indices demonstrated good external validation, exhibiting comparable performance to their respective validation groups (EVAR DeLong P = .891; OSR DeLong P = .757). CONCLUSIONS: ECI, the comorbidity index formulated for the general population, exhibited suboptimal performance in patients who underwent AAA repair. In response, we developed summary comorbidity indices for both EVAR and OSR for AAA repair, which were internally and externally validated. The EVAR and OSR comorbidity indices outperformed the ECI in discriminating in-hospital mortality rates. They can standardize comorbidity measurement for clinical studies in AAA repair, especially for studies with small samples such as single-institute data sources to facilitate replication and comparison of results across studies.
引用
- Li R, Sidawy A, Nguyen BN, et al. Development of a comorbidity index for patients undergoing abdominal aortic aneurysm repair. J Vasc Surg. 2023. PMID: 37890642. doi:10.1016/j.jvs.2023.10.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。